US probe into Ranbaxy puts Indian pharma in jeopardy
You must be signed in to read this analysis
In this article
- Settlement terms
- Ranbaxy's future
- Medium-to-long term costs
- Wider ramifications
- Heightened scrutiny of Indian plants
- Declining foreign investor interest
What is this?
This article is from the Oxford Analytica Daily Brief, which analyses geopolitical, economic, social, business and industrial developments on a global and regional basis, providing clients with timely, authoritative analysis every business day of the year. Find out more about the Oxford Analytica Daily Brief, or request a trial.